CNS Pharmaceuticals, Inc. SEC filings CNSP
CNS Pharmaceuticals, Inc. has 390 filings in SEC EDGAR's recent list, going back to Mar 13, 2018. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 2, 2026 (officer or director change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Oct 2, 2026 | Sep 30, 2026 |
| DEFA14A | Additional proxy material | Aug 25, 2026 | — |
| DEF 14A | Proxy statement | Aug 21, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 2, 2026 | Jul 2, 2026 |
| EFFECT | Filing | May 26, 2026 | — |
| 424B3 | Prospectus | May 26, 2026 | — |
| CORRESP | Letter to the SEC | May 22, 2026 | — |
| UPLOAD | Letter from the SEC | May 22, 2026 | — |
| D | Filing | May 19, 2026 | — |
| S-3 | Shelf registration | May 19, 2026 | — |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
May 4, 2026 | May 4, 2026 |
| 10-K/A | Amended annual report | Apr 30, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 11, 2026 | Mar 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 2, 2026 | Feb 26, 2026 |
| S-8 | Employee stock plan registration | Feb 27, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Feb 17, 2026 | Feb 10, 2026 |
| 8-K |
Current report
Officer or director change
|
Dec 17, 2025 | Dec 16, 2025 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Nov 21, 2025 | Nov 17, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| DEFA14A | Additional proxy material | Nov 12, 2025 | — |
| ARS | Annual report to shareholders | Oct 28, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Oct 24, 2025 | Nov 17, 2025 |
| PRE 14A | Preliminary proxy statement | Oct 10, 2025 | Nov 17, 2025 |
| 424B5 | Prospectus supplement | Sep 19, 2025 | — |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Jul 22, 2025 | Jul 17, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 15, 2025 | Jul 15, 2025 |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Material agreement
|
May 15, 2025 | May 13, 2025 |
| 424B4 | Prospectus | May 14, 2025 | — |
| EFFECT | Filing | May 13, 2025 | — |
| CORRESP | Letter to the SEC | May 12, 2025 | — |
| CORRESP | Letter to the SEC | May 12, 2025 | — |
| S-1/A | Amended registration statement | May 12, 2025 | — |
| 10-K/A | Amended annual report | Apr 30, 2025 | Dec 31, 2024 |
| CORRESP | Letter to the SEC | Apr 17, 2025 | — |
| CORRESP | Letter to the SEC | Apr 17, 2025 | — |
| CORRESP | Letter to the SEC | Apr 14, 2025 | — |
| CORRESP | Letter to the SEC | Apr 14, 2025 | — |
| S-1 | Registration statement | Apr 14, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 11, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 9, 2025 | Apr 9, 2025 |
| DRSLTR | Filing | Apr 7, 2025 | — |
| DRS | Filing | Apr 7, 2025 | — |
| 8-K |
Current report
Other events
|
Mar 31, 2025 | Mar 31, 2025 |
| 10-K | Annual report | Mar 31, 2025 | Dec 31, 2024 |
| 424B5 | Prospectus supplement | Mar 20, 2025 | — |
| 8-K |
Current report
Other events
|
Mar 20, 2025 | Mar 20, 2025 |
| 8-K |
Current report
Change to shareholder rights, Other events
|
Feb 21, 2025 | Feb 19, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 3, 2025 | Jan 3, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 11, 2024 | Dec 11, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Dec 3, 2024 | Nov 26, 2024 |
| DEFR14A | Definitive revised proxy soliciting materials | Nov 15, 2024 | — |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Other events
|
Nov 1, 2024 | Oct 30, 2024 |
| DEF 14A | Proxy statement | Oct 28, 2024 | Nov 26, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 24, 2024 | Oct 23, 2024 |
| 424B5 | Prospectus supplement | Oct 24, 2024 | — |
| 8-K |
Current report
Other events
|
Oct 23, 2024 | Oct 23, 2024 |
| PRE 14A | Preliminary proxy statement | Oct 15, 2024 | Nov 26, 2024 |
| 8-K |
Current report
Listing notice
|
Sep 18, 2024 | Sep 12, 2024 |
| 8-K |
Current report
Listing notice
|
Sep 12, 2024 | Sep 10, 2024 |
| 10-Q | Quarterly report | Aug 14, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Other events
|
Aug 7, 2024 | Aug 6, 2024 |
| EFFECT | Filing | Aug 2, 2024 | — |
| RW | Request for withdrawal | Jul 31, 2024 | — |
| 424B3 | Prospectus | Jul 30, 2024 | — |
| 8-K |
Current report
Other events
|
Jul 30, 2024 | Jul 30, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jul 30, 2024 | Jul 29, 2024 |
| 424B5 | Prospectus supplement | Jul 26, 2024 | — |
| 8-K |
Current report
Material agreement
|
Jul 26, 2024 | Jul 26, 2024 |
| 8-K |
Current report
Listing notice
|
Jul 24, 2024 | Jul 19, 2024 |
| S-1/A | Amended registration statement | Jul 19, 2024 | — |
| S-1 | Registration statement | Jul 12, 2024 | — |
| 8-K/A |
Amended current report
Other events
|
Jul 12, 2024 | Jul 5, 2024 |
| 8-K |
Current report
Other events
|
Jul 9, 2024 | Jul 5, 2024 |
| 424B5 | Prospectus supplement | Jul 5, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jul 3, 2024 | Jul 3, 2024 |
| 424B5 | Prospectus supplement | Jun 27, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jun 26, 2024 | Jun 26, 2024 |
| 8-K/A | Amended current report | Jun 20, 2024 | Jun 14, 2024 |
| 424B5 | Prospectus supplement | Jun 17, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jun 14, 2024 | Jun 14, 2024 |
| S-1 | Registration statement | Jun 10, 2024 | — |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Jun 5, 2024 | Jun 3, 2024 |
| EFFECT | Filing | May 17, 2024 | — |
| 8-K |
Current report
Results of operations
|
May 16, 2024 | May 16, 2024 |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| CORRESP | Letter to the SEC | May 15, 2024 | — |
| UPLOAD | Letter from the SEC | May 15, 2024 | — |
| S-3 | Shelf registration | May 9, 2024 | — |
| 8-K |
Current report
Other events
|
May 7, 2024 | May 6, 2024 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
May 3, 2024 | Apr 30, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 15, 2024 | Apr 9, 2024 |
| DEF 14A | Proxy statement | Apr 10, 2024 | Apr 30, 2024 |
| 8-K |
Current report
Results of operations
|
Apr 1, 2024 | Apr 1, 2024 |
| 10-K | Annual report | Apr 1, 2024 | Dec 31, 2023 |
| PRE 14A | Preliminary proxy statement | Mar 28, 2024 | Apr 30, 2024 |
| 8-K |
Current report
Listing notice, Officer or director change
|
Feb 27, 2024 | Feb 21, 2024 |
| 8-K |
Current report
Listing notice
|
Feb 21, 2024 | Feb 14, 2024 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Feb 2, 2024 | Jan 29, 2024 |
| 424B4 | Prospectus | Jan 31, 2024 | — |
| EFFECT | Filing | Jan 29, 2024 | — |
| CORRESP | Letter to the SEC | Jan 26, 2024 | — |
| CORRESP | Letter to the SEC | Jan 26, 2024 | — |
| CORRESP | Letter to the SEC | Jan 25, 2024 | — |
| CORRESP | Letter to the SEC | Jan 25, 2024 | — |
| CORRESP | Letter to the SEC | Jan 24, 2024 | — |
| CORRESP | Letter to the SEC | Jan 24, 2024 | — |
| 8-K |
Current report
Officer or director change
|
Jan 23, 2024 | Jan 17, 2024 |
| S-1/A | Amended registration statement | Jan 22, 2024 | — |
| CORRESP | Letter to the SEC | Jan 18, 2024 | — |
| CORRESP | Letter to the SEC | Jan 18, 2024 | — |
| CORRESP | Letter to the SEC | Jan 16, 2024 | — |
| CORRESP | Letter to the SEC | Jan 16, 2024 | — |
| S-1/A | Amended registration statement | Jan 10, 2024 | — |
| CORRESP | Letter to the SEC | Dec 26, 2023 | — |
| CORRESP | Letter to the SEC | Dec 26, 2023 | — |
| CORRESP | Letter to the SEC | Dec 21, 2023 | — |
| CORRESP | Letter to the SEC | Dec 21, 2023 | — |
| CORRESP | Letter to the SEC | Dec 21, 2023 | — |
| CORRESP | Letter to the SEC | Dec 21, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 21, 2023 | Dec 21, 2023 |
| CORRESP | Letter to the SEC | Dec 20, 2023 | — |
| CORRESP | Letter to the SEC | Dec 20, 2023 | — |
| CORRESP | Letter to the SEC | Dec 20, 2023 | — |
| CORRESP | Letter to the SEC | Dec 20, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 18, 2023 | Dec 18, 2023 |
| CORRESP | Letter to the SEC | Dec 14, 2023 | — |
| CORRESP | Letter to the SEC | Dec 14, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2023 | — |
| S-1 | Registration statement | Dec 8, 2023 | — |
| EFFECT | Filing | Nov 30, 2023 | — |
| 424B3 | Prospectus | Nov 30, 2023 | — |
| CORRESP | Letter to the SEC | Nov 28, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 28, 2023 | — |
| S-8 | Employee stock plan registration | Nov 22, 2023 | — |
| S-3 | Shelf registration | Nov 20, 2023 | — |
| 8-K |
Current report
Results of operations
|
Nov 15, 2023 | Nov 15, 2023 |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 18, 2023 | Oct 18, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 17, 2023 | Oct 16, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Sep 19, 2023 | Sep 14, 2023 |
| 8-K |
Current report
Listing notice
|
Aug 18, 2023 | Aug 17, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 15, 2023 | Aug 11, 2023 |
| DEF 14A | Proxy statement | Aug 14, 2023 | Sep 14, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2023 | Aug 14, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
May 15, 2023 | May 15, 2023 |
| 10-Q | Quarterly report | May 15, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 8, 2023 | May 3, 2023 |
| 10-K/A | Amended annual report | May 1, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 31, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 3, 2023 | Dec 30, 2022 |
| 8-K |
Current report
Other events
|
Dec 14, 2022 | Dec 13, 2022 |
| 424B4 | Prospectus | Dec 5, 2022 | — |
| 8-K |
Current report
Material agreement, Other events
|
Dec 1, 2022 | Nov 30, 2022 |
| EFFECT | Filing | Nov 30, 2022 | — |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Nov 28, 2022 | Nov 28, 2022 |
| CORRESP | Letter to the SEC | Nov 28, 2022 | — |
| CORRESP | Letter to the SEC | Nov 28, 2022 | — |
| S-1/A | Amended registration statement | Nov 28, 2022 | — |
| CORRESP | Letter to the SEC | Nov 15, 2022 | — |
| S-1/A | Amended registration statement | Nov 15, 2022 | — |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| UPLOAD | Letter from the SEC | Nov 4, 2022 | — |
| 8-K |
Current report
Other events
|
Oct 24, 2022 | Oct 21, 2022 |
| S-1 | Registration statement | Oct 21, 2022 | — |
| 8-K |
Current report
Shareholder vote results
|
Aug 26, 2022 | Aug 25, 2022 |
| 8-K |
Current report
Other events
|
Aug 19, 2022 | Aug 18, 2022 |
| 8-K |
Current report
Other events
|
Aug 16, 2022 | Aug 16, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 15, 2022 | Aug 15, 2022 |
| 10-Q | Quarterly report | Aug 12, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Other events
|
Aug 4, 2022 | Aug 3, 2022 |
| 8-K |
Current report
Other events
|
Jul 28, 2022 | Jul 27, 2022 |
| DEF 14A | Proxy statement | Jul 7, 2022 | Jul 27, 2022 |
| PRE 14A | Preliminary proxy statement | Jun 27, 2022 | Jul 27, 2022 |
| 8-K |
Current report
Results of operations
|
May 16, 2022 | May 16, 2022 |
| 10-Q | Quarterly report | May 13, 2022 | Mar 31, 2022 |
| 10-K/A | Amended annual report | Apr 29, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 3, 2022 | Mar 3, 2022 |
| 10-K | Annual report | Mar 3, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Listing notice
|
Feb 18, 2022 | Feb 18, 2022 |
| 424B3 | Prospectus | Feb 1, 2022 | — |
| EFFECT | Filing | Jan 31, 2022 | — |
| CORRESP | Letter to the SEC | Jan 28, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 26, 2022 | — |
| S-3 | Shelf registration | Jan 20, 2022 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 10, 2022 | Jan 10, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jan 6, 2022 | Jan 5, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 3, 2021 | Dec 3, 2021 |
| 10-Q | Quarterly report | Nov 12, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2021 | Aug 13, 2021 |
| 10-Q | Quarterly report | Aug 13, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 19, 2021 | Jul 19, 2021 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jul 1, 2021 | Jun 28, 2021 |
| DEF 14A | Proxy statement | Jun 8, 2021 | Jun 28, 2021 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNSP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1729427
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.